DPI developer Iconovo has announced that a PK study of its ICOres reservoir-based inhaler demonstrated that the device delivered a budesonide/formoterol dry powder formulation as expected compared to Symbicort Turbuhaler.
According to the company, the clinical study, which enrolled 29 healthy volunteers, showed “slightly higher values for ICOres” related to delivery of the formoterol component and “excellent correspondence with regards to budesonide.”
Iconovo CEO Orest Lastow said, “We are happy that we now for the first time can demonstrate that ICOres together with the formulation also developed by Iconovo, work in humans. The results from the clinical study was above our expectations, and I now look forward to start the final phase of the development project.”
Read the Iconovo press release.
